According to OmniActive, Everstone’s funding made it possible for OmniActive to acquire an 85% stake in Bangalore, India–based botanical extracts supplier Indfrag Ltd.
Photo © iStockphoto.com/ilyast
OmniActive Health Technologies announced new company developments in recent weeks. First, the company reports that private-equity group The Everstone Group has invested $35 million in OmniActive “to further accelerate its growth in the fast-expanding nutraceuticals space.”
According to OmniActive, Everstone’s funding made it possible for OmniActive to acquire an 85% stake in Bangalore, India–based botanical extracts supplier Indfrag Ltd., particulary Indfrag’s botanical ingredients for the food and nutrition industry, including Garcinia cambogia, green coffee, natural caffeine, valerian, turmeric, boswellia, fenugreek, guarana, and more.
According to OmniActive, the acquisition signals OmniActive’s continued commitment to supplying natural extracts. “The company holds a leadership position in standardized plant extracts. Further, with their strong footprint at the source, they have developed a library of over 100 botanicals, which provides a strong foundation for launching products that complement OmniActive’s innovation platform in meeting emerging industry and consumer needs,” said Sanjaya Mariwala, managing director and CEO for OmniActive Health Technologies Ltd., in a press release.
The following individuals will join Indfrag’s board: Mariwala; Deep Mishra, managing director at Everstone India; and Chaitanya Desai, COO of OmniActive. Indfrag’s founder, Philip Samuel, will remain chairman of the board.
OmniActive says it will use Everstone’s funding to diversify and expand its product line. The OmniActive deal is said to be Everstone’s third deal in the health and wellness market in less than a year.
Jennifer Grebow
Editor-in-Chief
Nutritional Outlook magazine
jennifer.grebow@ubm.com
Kaneka Nutrients to unveil new consumer research on menopausal women at Vitafoods Europe 2024
April 26th 2024The company will reveal the results of the research that is based on live feedback from 200 menopausal women who took 200 mg per day of Kaneka Ubiquinol over two-months, monitored the effects, and recorded their observations.
Rousselot to showcase new collagen peptide research and targeted solutions at Vitafoods Europe 2024
April 25th 2024The company will be highlighting new research that demonstrates the ability of its Peptan collagen peptide brand to support sleep quality, reduce gastrointestinal discomfort, and enhance skin health, including density, hydration, and elasticity.